BMJ GUT (2019)

Study Summary

Improved Adenoma Detection with ENDOCUFF VISION™: The Adenoma Randomized Controlled Trial

Ngu, Wee Sing; Bevan, Roisin; Tsiamoulos, Zachary P; Bassett, Paul; Hoare, Zoe; Rutter, Matthew D; Clifford, Gayle; Totton, Nicola; Lee, Thomas J; Ramadas, Arvind; Silcock, John G; Painter, John; Neilson, Laura J; Saunders, Brian P; Rees, Colin J

DOI: 10.1136/gutjnl-2017-314889

Conclusion

ENDOCUFF VISION™ significantly enhances the adenoma detection rate in patients in the UK bowel cancer screening program in comparison to standard colonoscopy.

Objective

To evaluate the impact of ENDOCUFF VISION™ on the adenoma detection characteristics in a colorectal cancer screening population.

Design

Multicenter randomized controlled trial comparing ENDOCUFF VISION™-assisted colonoscopy to standard colonoscopy; enrollment of patients from seven hospitals and 48 colonoscopists in the UK.

Indication

Patients referred to colonoscopy as part of the postpolypectomy surveillance program or patients part of the Bowel Cancer Screening Program with a positive fecal occult blood test (FOBT).

Participants

Within the study, 884 patients were enrolled into the standard colonoscopy (SC) arm and 888 in the ENDOCUFF VISION™ arm. Of all patients, 797 were part of the UK Bowel Cancer Screening Program (BCSP) with a positive FOBT (SC n= 403; ENDOCUFF VISION™ n= 394). All other patients were non-BCSP patients and therefore not tested with a FOBT.

Results

- ENDOCUFF VISION™ significantly improved the ADR in the total population by 4.7 percentage points (SC 36.2% vs. ENDOCUFF VISION™ 40.9%; p <0.001).
- In the FOBT-positive subgroup ENDOCUFF VISION™ substantially improved ADR by 10.8 percentage points (SC 50.9% vs. 61.7% ENDOCUFF VISION™; p <0.001).
- Additionally, patients screened with ENDOCUFF VISION™ had higher mean adenomas per procedure and a larger number of left-sided, diminutive and small adenomas.
- No difference in adverse events was detected between the two groups.

Key Findings

ENDOCUFF VISION™ significantly increases the adenoma detection rate in a screening population, most clearly in a FOBT+ population.

OLYMPUS EUROPA SE & CO. KG
Postbox 10 49 08, 20034 Hamburg, Germany
Wendenstrasse 14-18, 20097 Hamburg, Germany
Phone: +49 40 23773-0, Fax: +49 40 233765
www.olympus-europa.com